U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07044544) titled 'Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies' on June 23.
Brief Summary: The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Myeloid Malignancy
Hematologic Malignancy
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Intervention:
DRUG: G-CSF
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein that stimulates the bone marrow to produce...